The infrastructure layer for upper airway dysfunction.

Somnus is an airway platform company. We treat obstructive sleep apnea as a chronic condition — not a one-time surgical event — and we built the company to match that reality.

We are building the loop.

88%	$2,500	12	390+
HYPNARA™ GROSS MARGIN	ASP PER PROCEDURE	U.S. PATENT APPLICATIONS FILED	CLAIMS OVER NEXT 12 MONTHS

Somnus Technologies, Inc.

THE DE-RISKING STORY

FDA-classification de-risked on the software side: counsel review concludes the Somnus Sleep™ app, the BSA™ acoustic engine, and the Somnus Index™ fit within the FDA General Wellness Policy.

The Somnus Sleep™ app turns any smartphone into a sensor via BSA™, our on-device acoustic breathing and snoring engine — zero hardware, zero cost to enter the funnel. The Somnus Index™ is a composite wellness score that tracks progression across the platform. Both operate under the FDA General Wellness Policy and are positioned in wellness terms.

Somnus Index™ is a wellness metric under FDA General Wellness Policy. Not a medical device.

Not a device gap. It's an infrastructure gap. The market keeps shipping better open-loop products into a problem that only a closed loop can solve.

What we're building, in our own words

We're building the infrastructure layer for upper airway dysfunction (UAD).

The clinical wedge is HYPNARA™, a palatal implant with strong unit economics: $2,500 ASP, $300 COGS, 88% gross margin, break-even at two thousand units. At its May 7, 2026 FDA Pre-Submission meeting, Somnus reviewed the regulatory pathway for HYPNARA™. **FDA did not raise concerns on the 510(k) pathway or the Pillar predicate (K040417).** FDA indicated that a clinical study evaluating both safety and effectiveness will be required to support the change in implant material; study design, sample size, and protocol will be addressed in a supplemental Q-submission, and the 510(k) submission follows study completion. Somnus is in final evaluation of clinical research organizations to run the study. That's the near-term commercial story.

— Unit economics & IP trajectory

HYPNARA™ unit economics



88%
gross margin

~2,000
units to break-even

IP portfolio trajectory — next 12 months

Every product makes the others more valuable



Every treated patient sharpens routing for the next.

Sensors → Bedside Node → Somnus Index™ → Provider Directory → Therapy → Outcomes → Re-scoring & Re-routing → back to Sensors. **We are building the loop.**

Seven pieces, one flywheel

CLINICAL WEDGE

HYPNARA™

Palatal implant for snoring and mild-to-moderate OSA. 510(k) via Pillar predicate (K040417), Voltas Medical (ISO 13485). Passive structural device; AI/ML decision layer in the surrounding software. Pre-Sub complete (May 7) — FDA did not raise pathway or predicate concerns; safety-and-effectiveness clinical study required; CRO selection in final evaluation; submission follows study.

$2,500 ASP · 88% GM · ~2,000 units

ORAL DEVICE ARM

MORPHEX™AI

A smart oral device with on-device airway analytics, supported by an AI/ML clinical decision layer. Ships in three regulatory stages so each stage funds the next; supports clinical decision-making and does not diagnose independently.

V1 MAD → V2 wellness → V3 diagnostic

TOP OF FUNNEL

Somnus Sleep™ + BSA™

Turns any smartphone into a sensor via BSA™, our on-device acoustic breathing and snoring engine. Zero hardware, zero cost to enter the funnel. Machine-learned acoustic classification with per-patient calibration.

Pre-launch · FDA General Wellness Policy-aligned

THE SCORE

Somnus Index™

Composite wellness score that tracks progression across the platform. Patient-facing in the app, provider-facing in the Directory. Operates under the FDA General Wellness Policy and is positioned in wellness terms.

Core of the defensible moat

PROVIDER INTERFACE

Somnus Provider Directory™

Launch: patient-browsable directory of sleep-health providers from public registry data (NPPES). Neutral, informational — no credentialing claim, no selective routing — in the wellness context.

Roadmap (V3): predictive, selective routing layer and provider worklist is a roadmap capability on the device-software track; pathway under counsel review.

PREMIUM TIER · ROADMAP

Somnus Bedside Node™

Premium-tier bedside hardware with mmWave radar and beamforming mics. Extends BSA™ and the Somnus Index™ beyond the phone, and pairs with the MORPHEX™AI V3 diagnostic tier when that stage activates. Multi-modal sensor fusion with graceful degradation.

Roadmap — aligns with MORPHEX™AI V3

— The Moat

The post-therapy outcome data nobody else captures is our training set.

The Long-Term Moat Is the Closed-Loop Data Network

The seven pieces are the components; the loop that connects them — sense, score, route, treat, re-score — is the durable asset. We are building the loop. As one connected system it does not exist in the market today, and it is the subject of multiple patent-pending applications across the closed-loop architecture, scoring, routing, and sensor-fusion claim families.

We're not selling a device. We're building the infrastructure layer for upper airway dysfunction.

Maturity reflects build status, not accumulated usage.

What the round funds

Use of proceeds. First-close capital funds HYPNARA™ through the FDA-required clinical study and 510(k) submission, the Somnus Sleep™ launch, IP-portfolio expansion, and provider-network seeding. The full round adds the MORPHEX™AI V1 MAD 510(k) workstream.

- HYPNARA™ clinical study initiated and progressed toward 510(k) submission.
- Somnus Sleep™ launched; early engagement traction.
- IP portfolio expanded toward ~19 applications / 390+ claims.
- Provider network seeded (neutral, public-registry-sourced directory at launch).
- MORPHEX™AI V1 MAD 510(k) workstream underway (full-round capital).

05 · THE ASK

Terms & structure

$3–5M	$20–24M	Single entity	$2.5M	10–12 wk
TARGET RAISE	PRE-MONEY	STRUCTURE · SAFE	FIRST CLOSE	CLOSE TIMELINE

- **Round —** one round, one entity; $3M–$5M at $20M–$24M pre-money. **Option pool —** 10% reserved at close. **Board —** three seats: Founder/CEO, Lead Investor, Independent.
- **Issuer —** Somnus Technologies, Inc., a Wisconsin C-corporation, single entity through seed close. **Use of proceeds —** HYPNARA™ launch · MORPHEX™AI V1 · Somnus Index™.

An F-reorganization (IRC §368(a)(1)(F)) to a destination jurisdiction is planned pre-Series A and is investor-contingent; the destination is open. The HoldCo + two-subsidiary structure (Somnus Medical Devices, Inc. + Somnus Digital Health, Inc.) is a Phase-2, pre-Series A event.

06 · ADVISORS

The room we've built around this

John R. McDonald — Shareholder · Chair, Startups & VC · Godfrey & Kahn, S.C.

Amy Salmela — Partner · U.S. Patent Attorney · EIP

Jeffrey K. Shapiro — Partner · FDA & Life Sciences · King & Spalding LLP

Agustin J. Arrieta, MD — Otolaryngology / Sleep Medicine · Clinical advisor.

Mike Kremkau — Strategic Advisor · Industry veteran.

Matthew Cronin · Founder & CEO

mcronin@somnustech.ai

Book 10 minutes with me →

"On any full clinic day, I see three to five patients presenting with snoring concerns — sometimes more. The demand for a single-procedure palatal solution is steady and underserved by today's options." — Agustin J. Arrieta, MD